伴随性疾病的性别差异与心力衰竭的缺血性中风患者的血栓抑制疗法排除相关:一项追溯数据分析
Jonah Joffe1, Ryan Stepp1, Madisen Faulkner1
1University of South Carolina School of Medicine, Greenville, USA.
JRSM cardiovascular disease
|February 12, 2026
概括
对于rtPA治疗的基线风险因素在男性和女性心力衰竭急性缺血性中风 (AIS-HF) 患者之间不同. 动脉狭窄的男性患者被排除在外,而患有慢性病的女性则被排除在外.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 内部医学 内部医学
背景情况:
- 带有心力衰竭的急性缺血性中风 (AIS-HF) 是一种复杂的疾病,需要及时治疗.
- 血栓缓解疗法,如rtPA (重组组织等离子体激活剂),对于改善结果至关重要.
- 了解影响AIS-HF中rtPA资格的基线风险因素对于优化治疗策略至关重要.
研究的目的:
- 确定与包括和排除AIS-HF患者从rtPA治疗相关的基线风险因素.
- 为了确定这些基线风险因素是否在男性和女性AIS-HF患者之间存在差异.
主要方法:
- 对PRISMA健康中风登记册的回顾性数据分析.
- 开发物流回归模型来计算风险因素的赔率比率 (OR).
- 对590名AIS-HF患者的分析,按性别分层.
主要成果:
- 患有冠状动脉狭窄症 (CAS) 的男性AIS-HF患者在rtPA中被排除的几率更高 (OR=0.279).
- 患有慢性病 (CRD) 的女性AIS-HF患者在rtPA中被排除的几率更高 (OR=0.159).
- 较高的国家卫生研究院中风量表 (NIHSS) 评分增加了两种性别的纳入可能性,而抗抑郁药的使用与女性更高的纳入相关.
结论:
- 性别特定的基线因素影响了AIS-HF患者的rtPA资格.
- 动脉狭窄是男性的显著排除因素,女性的慢性病.
- 制定量身定制的管理策略是必要的,以提高在男性和女性AIS-HF人群中rtPA的利用率.
相关概念视频
Heart Failure VI: Adjunct Therapies
395
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction
951
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management
360
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
360


